Lilly's New Weight-loss Pill Shows Promise in Study

A recent study shows patients did not regain significant weight after switching from injectable GLP-1 medication to Eli Lilly's new weight-loss pill, Foundayo. Transitioning from Novo Nordisk's Wegovy led to minimal weight gain, while switching from Lilly's Zepbound resulted in an average gain of 11 pounds.

Eli Lilly's new weight-loss pill Foundayo exhibited promising results in a recent study. Patients transitioning from long-term injectable GLP-1 medications did not experience substantial weight gain after a year on the pill.

According to study results presented at an obesity conference, those who switched from Novo Nordisk's Wegovy to Foundayo regained merely 2 pounds on average. However, patients transitioning from Lilly's more potent Zepbound injectable saw an average weight gain of 11 pounds.

This study underscores the potential of oral medications in long-term weight management, offering alternatives to injectables with comparable efficacy.